SOPHiA GENETICS provides AI-driven genomic and radiomic analysis through its SOPHiA DDM platform, used by oncologists, radiologists, pathologists, and geneticists at more than 1,000 healthcare institutions across 75-plus countries. The company reports 98-99% accuracy using advanced AI analytics across more than 2.6 million genomic profiles analyzed to date, covering solid tumors, blood cancers, hereditary cancers, liquid biopsy, and rare or inherited disorders.
Scale is what makes the accuracy claim meaningful here – 98-99% accuracy measured across 2.6 million profiles is a materially different statement than the same figure from a small validation study, and processing thousands of patient profiles weekly across a global institution network gives the underlying models continuous real-world signal that a narrower deployment couldn’t match. Add-on modules like Alamut Visual Plus (variant interpretation) and OncoPortal extend the core platform into more specialized clinical workflows.
This is enterprise healthcare-genomics infrastructure built for institutions, not individual clinicians or consumers – cloud infrastructure is built for HIPAA and GDPR compliance given the sensitivity of the data involved. Pricing isn’t disclosed on the homepage; expect an institutional sales process.
